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Research
AbstrACt
Objective To evaluate the age appropriateness and 
suitability of patient-reported outcome measures to assess 
the acceptability of the taste of oral liquid medicines in 
children.
Design and setting An observational mixed-methods 
study involving children aged 2–16 years taking oral liquid 
medicine in paediatric inpatient wards across the West 
Midlands (UK). Assessment tools included patient-reported 
scores on the taste of medicines via a five-point Facial 
Hedonic Scale; a Visual Analogue Scale (VAS); a question, 
‘Did you think the medicine tasted OK?’ and researcher 
observations of facial expressions and behaviours 
immediately before, during and after administration.
results 611 children participated. The percent unable 
to complete the scales was 7% (n=46) for the VAS; 
2% (n=15) for the hedonic scale and 1% (n=7) for the 
question about taste. Significant correlations (Spearman’s 
r) were observed between the patient-reported outcome 
measures: 0.80 and 0.78 for the taste question and 
hedonic and VAS, respectively, and 0.84 for the hedonic 
and VAS. Researcher observations demonstrated the ability 
of the patient to take the medicine as intended but did not 
provide sensitive measures of taste. 5% of administrations 
were not taken as intended by the children. Medicines 
known to have poor taste (clarithromycin and 
prednisolone) showed mean hedonic and VAS scores of 
≥3.5 and >65 mm, respectively.
Conclusions Patient-reported outcome measures 
correlate with each other and are a useful means to 
assess the taste (and acceptability) of medicines. Hedonic 
scales are better understood by children and should be the 
first choice tool in the assessment of medicines taste.
IntrODuCtIOn 
Measurement of acceptability of paedi-
atric medicines is important for two major 
reasons: (1) poor acceptability is likely to be 
associated with poor compliance and there-
fore suboptimal therapy; (2) regulatory 
guidelines dictate that paediatric medicines’ 
acceptability should be assessed (preferably 
in children).1 Patient acceptability has been 
defined as, ‘an overall ability of the patient 
and caregiver (defined as ‘user’) to use a 
medicinal product as intended (or autho-
rised)’.1 A major barrier in the assessment of 
acceptability and subsequent interpretation 
of results is the lack of guidance on how an 
acceptability test should be conducted and 
the criteria used to determine acceptability in 
children.2 It is unlikely that a single accept-
ability test will be valid for all medicines, 
due to the need to consider the benefit–risk 
balance on an individual basis.
Taste was previously identified as the biggest 
barrier in adherence and compliance in a 
paediatric population.3 Previous techniques 
to evaluate acceptability focused on taste and 
strengths and limitations of this study
 ► This is the first study to compare methodologies to 
assess the acceptability of taste of liquid medicines 
in a large UK-based paediatric population aged 
2–16 years.
 ► The sample size in this study provided large data 
sets of six key medicines, which provides a repre-
sentative comparison for newly developed products.
 ► This study was conducted within an inpatient envi-
ronment and the acceptance of taste of medicines in 
a domiciliary environment may differ.
 ► The study design captured the most relevant as-
pects of acceptability of taste while minimising the 
burden to participants, it was not possible to mea-
sure every aspect. Suggestions for future research 
include measurement of: impact of the devices used 
to administer medicines; use of alternative hedonic 
scales (eg, those with two to nine faces); alterna-
tive anchor phrases; an endpoint of neutral and not 
positive within a hedonic scale; further exploration 
of medicines that tasted OK as well as those with a 
reported negative taste.
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were based on methodology adapted from sensory anal-
ysis undertaken in the food industry. A variety of scales 
have been used to measure the acceptability of medi-
cines, yet it remains unclear whether any of the scales 
is better for a particular purpose with regard to validity, 
reliability, feasibility and preference.4 5 Patient-reported 
measures of taste offer a pragmatic means to collect data 
on products. However, there is often concern about the 
reliability of these measures, particularly in a paediatric 
population.6 Sensory analysis is commonly used to show 
a preference for one product over another, but this is not 
always relevant to medicines as often there is no alterna-
tive available. In addition, it can be rationalised that the 
therapeutic benefits of medicines outweigh the negative 
taste. It is complex to distinguish between acceptability 
and likeability of a medicine’s taste, yet this difference 
may be critical for appropriate interpretation of resulting 
data.
The validity of any new method relies on how well it 
compares to other measures.7 The development of a 
reliable method to assess the taste of medicines requires 
comparison of a variety of tools. This study compares a 
range of methods to assess the taste of medicines within 
a large paediatric inpatient population. Independent 
researcher observations are also compared with the 
self-reported data. The results of this study will be used 
to propose a suitable method that can be used for future 
taste assessments.
MAterIAls AnD MethODs
Three patient-reported outcome (PRO) measures were 
compared with each other, and to researcher observations 
of medicines administration in an observational mixed-
methods study.
Patient and public involvement
Bespoke PRO tools were developed for this study based 
on previous methodologies and in consultation with the 
National Institute for Health Research Children Special-
ty’s Young Person’s Advisory Group (West Midlands).8 The 
young people (aged 11–18 years) reviewed the tools and 
provided feedback that the tools were age appropriate. 
The same young people provided feedback on the trial 
materials including information sheets and how to mini-
mise the burden to participants during the conduct of the 
study. The results are available to participants as a poster 
summary from the corresponding author’s personal 
webpage (www. hannahbatchelor. com); this poster was 
also reviewed by the young person’s group.
PrO measures used
The hedonic scale selected was a genderless image where 
the mouth was the only expressive facial feature (see 
figure 1A). The images were yellow to ensure they stood 
out from the background paper. They were obtained 
from S-cool the revision website (http://www. s- cool. co. 
uk/ gcse/ food- technology/ systems- and- control/ revise- it/ 
sensory- evaluation (accessed December 2015)). Children 
and young people preferred simple faces and felt that this 
would be most appropriate for the youngest age group8; 
anchor phrases were not included on the hedonic scale 
to keep this tool basic. The Visual Analogue Scale (VAS) 
included anchor phrases selected by the young persons’ 
group as the most clear and relevant,8 these were used at 
the extreme ends of the continuous scale.
Figure 1 Scales used within PRO tools completed by paediatric participants immediately after administration of their 
medicine. (A) Hedonic scale; (B) Anchored Visual Analogue Scale; (C) direct question on taste. PRO, patient-reported outcome.
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The direction of change was from positive to negative, 
which corresponds to the extensive data on hedonic scales 
used for pain assessment in children.9 Previous studies 
in adult studies of foods showed no difference based on 
structural variations that read from positive to negative or 
vice versa.10
The third PRO was a question, ‘Did you think the medi-
cine tasted OK?’ with the response options of: yes, no, not 
sure.
Participants and setting
Paediatric inpatients aged between 2 and 16 years taking 
any oral liquid medicine as part of their medical care 
were recruited using convenience sampling, from inpa-
tient wards at 11 sites across the West Midlands. Informed 
consent was obtained from the parent or legal guardian 
of the participating child and for children over 12 years 
of age assent was also required. The study was conducted 
between December 2015 and April 2016. 
Demographic information was obtained on partic-
ipant’s age and whether this was their first dose of the 
medicine under evaluation. The medicine name, brand, 
manufacturer, concentration (strength), dose adminis-
tered and product batch number were recorded.
Each participant was observed by a researcher as they 
took their medicine. Some medicines were provided to 
the patient as an oral liquid following extemporaneous 
preparation within the clinical setting, for example, 
dispersion of prednisolone tablets immediately prior to 
dosing. Depending on the capability of the child, the 
medicines were either self-administered, or administered 
by nursing staff and/or parents. Participants were asked 
not to mix the medicine with any other food product, as 
this might influence the participant’s responses.
PrO tools
Participants were asked to complete (1) five-point Facial 
Hedonic Scale and (2) 10 cm VAS (figure 1A,B imme-
diately after administration of their medicine; both 
scales were provided on separate paper documents in a 
randomised order. Children were free to ask for support 
in completing the questionnaires from parents, nursing 
staff or the researcher present. The cognitive function of 
children was not assessed and age may not always predict 
a child’s ability to complete the questionnaire; therefore, 
all children were free to ask for support if required. Both 
reporting documents included a third PRO (figure 1C) as 
a question, ‘Did you think the medicine tasted OK?’ with 
the response options of: yes, no, not sure. The purpose 
behind this question was to endorse the reliability 
of the participant’s reporting from both scale-based 
questionnaires.
The data from the scales (figure 1A,B) were trans-
formed into numbers for subsequent statistical analysis. 
Hedonic expressions were converted to scores of 1–5 with 
1 being the most positive expression and 5the most nega-
tive. VAS scores were reported as measurements from 
the extreme left hand side of the scale in millimetre; this 
provided scores of 0–100 mm (although scale was written 
as 0–10 cm).
researcher observations
A facial expression and behavioural scale to capture 
researcher observations was a 12-point tick chart designed 
Figure 2 Researcher observation sheet completed by the researcher prior to, during and post medicine administration.
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in-house (figure 2), based on an existing scale used to 
measure behavioural distress in children undergoing 
medical procedures,11 the Procedural Behavior Rating 
Scale (PBRS). The PBRS was developed specifically 
for infants and children with cancer, who were under-
going bone marrow aspirations or lumbar punctures. 
It contained 13 behavioural codes including: cry, cling, 
pain verbal, flail, stall, scream, refuse position, restrain, 
emotional support, muscular rigidity and requests termi-
nation.11 The in-house tool was based on this scale plus, 
other scales used to measure behavioural distress in chil-
dren.12 The facial expressions included on the scale were 
derived from previous studies that assessed food liking in 
children based on their facial expressions; typically nega-
tive tastes are associated with eyes squeezing, brow bulge, 
nose wrinkle and pursed lips.13
A series of nine short films or still pictures of children 
were made available to researchers participating in the 
study to assess the inter-rater agreement in the facial 
expressions displayed.
statistical analysis
A sample size was not fixed for this study at the outset as 
there was no appropriate power calculation. Advice from 
a statistician was to ensure we had sufficient numbers 
(<50) paired data to ensure that selectivity and sensitivity 
of the methods could be demonstrated.
Initially, the mean age of participants who were unable 
to understand the assessments were compared with 
those who could using Mann-Whitney U tests. The same 
approach was also used to compare the scores for patients 
receiving their first dose, relative to those who had previ-
ously received the medicine. Age was then divided into 
categories, and the proportions of participants scoring in 
the extreme categories for the scales were compared using 
Fisher’s exact tests. Spearman’s correlation coefficients 
were used to assess the degree of correlation between the 
assessments for the cohort as a whole, and within each of 
the age categories. In this analysis, the ‘Did you think the 
medicine tasted OK?’ question was treated as an ordinal 
scale, with the response of Don’t Know being between 
Yes and No. Where responses were not recorded for all 
criteria, the outcome was calculated based on those that 
were available.
The assessments were then dichotomised, and 
compared using McNemar’s tests to assess for marginal 
homogeneity in the 2×2 tables, and Kappa to assess agree-
ment. The three assessments were then combined into 
a composite score, which was compared with reported 
behaviours using Kendall’s tau correlation coefficients. 
All analyses were performed using IBM SPSS V.22 (IBM), 
and p<0.05 deemed to be indicative of statistical signifi-
cance throughout.
results AnD DIsCussIOn
Data were available for 628 administrations to 611 chil-
dren aged between 2 and 16 years. The median participant 
age was 6 years. Further details on the distribution of the 
participant ages can be found in online supplementary 
material 1.
To ease analysis of data, the population for this study 
was stratified by age into three groups: 2–4 years (n=237), 
5–9 years (n=227) and 10–16 years (n=147).
The medicine was administered as the first dose in 162 
cases. There was no evidence of a significant difference in 
the hedonic or VAS scores between those receiving their 
first dose of a medicine, compared with those who had 
previous administrations (p=0.336, 0.909, respectively). 
For all subsequent analysis, the data were pooled for those 
receiving their first and subsequent doses of medicine.
Completeness of patient-reported assessment scales
The assessment scales were not completed by all of the 
study participants. The VAS had the lowest completion 
rate, where 46 (7%) were not completed due to lack of 
understanding by the child, compared with 15 (2%) for 
the hedonic scale. There were 7 (1%) cases where the 
child did not understand the question, ‘Did you think the 
medicine taste OK?’. The range and mean age of those 
unable to complete the scales were 2–5 years with a mean 
of 2.4 years for the hedonic; 2–6 years with a mean of 3.1 
years for the VAS and 2–3 years with a mean of 2.3 years 
for the taste question. In each case, participants unable 
to understand the assessment methods were significantly 
younger than the remainder of the cohort (p<0.001 each 
assessment). The cognitive function of children was not 
assessed within this study and there was an assumption of 
cognitive normal for age for all participants.
Distribution of responses to patient-reported assessment 
scales
In the patient-reported scales (VAS and hedonic), the 
responses tended to be biased towards the extreme 
responses, with 56% of responses being in the highest 
or lowest categories for hedonic score (figure 3A) and, 
55% within 1 cm from either end of the scale in the VAS 
(figure 3B).
The use of the extreme ends of the scales was greater 
in the younger populations (p<0.001) (data are shown 
in online supplementary material 2). For those that 
completed the hedonic scale, 64% of those aged 2–4 
years used the extreme ends of the scale compared with 
60% of those aged 5–9; 35% of those aged 10–16 years. A 
similar trend was observed in the VAS data where 66% of 
those aged 2–4 years were within 10 mm of either end of 
the scale compared with 60% of those aged 5–9 years and 
39% of those aged 10–16 years.
reliability of assessment, ‘Did you think the medicine tasted 
OK?’
The question, ‘Did you think the medicine tasted OK?’ 
was asked to participants on two occasions for each medi-
cine administration; once following the hedonic and once 
following the VAS (which were presented in a randomised 
order). In the 600 cases, where participants responded 
5Mistry P, et al. BMJ Open 2018;8:e021961. doi:10.1136/bmjopen-2018-021961
Open access
to both questions, the same response was given in 569 
(95%) of cases, giving a Kappa statistic of 0.91. In cases 
where the answers were not consistent, the median age 
of the respondents was 5 years (mean age=6.3 years). For 
subsequent analysis, the two versions of this question were 
merged, with discrepancies resolved by taking the most 
positive response given by the participant.
Correlation between PrO measures
Significant correlations were observed between the 
hedonic scale score, VAS and ‘Did you think the medi-
cines tasted OK?’ question (all p<0.001 table 1), with the 
strongest correlation observed between the hedonic and 
VAS scores (Spearman’s r=0.84). The weakest correla-
tions were consistently observed in the youngest patients 
(age 2–4 years), implying that this group of patients had 
the lowest consistency in scores given across the different 
assessments. However, despite this, the consistency 
between the scores was still reasonable, with correlation 
coefficients ranging from 0.68 to 0.77.
The assessments were dichotomised, to identify those 
responses that classified a medicine as tasting acceptable. 
For the hedonic scale, this was defined as a neutral to 
positive response (the leftmost three faces of figure 1A). 
For the ‘Did you think the medicine tasted OK?’ ques-
tion, grouping the ‘yes’ and ‘not sure’ responses was 
considered most appropriate, as the overall purpose is 
the assessment of acceptability of taste of a medicine; the 
response ‘no’ is clearly aligned to an unacceptable taste, 
making other responses acceptable. The level of agree-
ment between the resulting dichotomised scores was high 
(90%), with a Kappa statistic of 0.782 and no indication 
of bias (McNemar’s test: p=0.519).
Correlation of the hedonic scale to the ‘tastes OK’ ques-
tion is simple; however, interpretation of the VAS is more 
complex. The VAS had anchor phrases at either end to 
maintain the continuous scale, so it was not obvious where 
neutral or positive was ranked on the scale. Initially, an 
arbitrary cut-off of <50 mm in the VAS was used to define 
acceptability, which gave reasonable agreement with both 
the dichotomised hedonic (88%) and ‘tastes OK’ (86%) 
measures. However, McNemar’s test indicted significant 
bias in both cases (p<0.001), with a tendency for the 
VAS score of 0–50 mm to underestimate the number of 
tastes-acceptable responses, compared with the hedonic 
and ‘tastes OK’ assessments. As a result, alternative VAS 
cut-offs were explored, with 0–70 mm selected to approx-
imately match the cut-off on the hedonic scale where the 
neutral face becomes the negative. Using 70 mm rather 
than 50 mm in the VAS marginally increased the agree-
ment with both the dichotomised hedonic and ‘tastes 
OK’ measures to 91% but, more importantly, eliminated 
the previously observed bias (McNemar’s test p=1.000, 
0.683, respectively). All subsequent analysis used the 
cut-off of >70 mm as a measure of unacceptable taste.
Associations with researcher observations and PrO measures
One patient did not have a record of facial expression/
behaviours, hence they were excluded, and the analysis 
was based on n=620 cases. Associations between facial 
expressions and behaviours (listed in figure 2) were 
Figure 3 Hedonic and Visual Analogue Scale (VAS) score 
distribution.
Table 1 Spearman’s r correlation values between patient-
reported outcome measures
Overall
‘Tastes OK’ 
versus hedonic
‘Tastes OK’ 
versus VAS
Hedonic 
versus VAS
0.80 0.78 0.84
Age (years)
  2–4 0.77 0.68 0.76
  5–9 0.83 0.85 0.90
  10–16 0.80 0.81 0.86
VAS, Visual Analogue Scale.
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linked to cases where the medicines were reported to have 
an unacceptable taste, based on a composite outcome 
(table 2). This was defined using the criteria defined 
previously. Where responses were not recorded for all 
criteria, the outcome was calculated based on those that 
were available. In total, 255/620 (41%) of assessments 
identified the taste of medicines to be unacceptable. The 
associations between this outcome, and the various facial 
expressions and behaviours that were recorded were then 
assessed.
Table 2 shows the incidence of the facial expression 
or behaviour as a fraction of the total population. The 
behaviours are listed in order of Kendall’s tau correla-
tion coefficients, with those behaviours most strongly 
associated with unacceptable taste having the highest 
value of tau. Based on this metric, voicing disgust was the 
behaviour most strongly associated with negative taste. Of 
the 105 patients who voiced disgust, 95 (90%) reported 
the taste of the medicine to be negative. This rate was 
almost threefold higher than the 160/515 (31%) who 
reported negative taste after not voicing disgust. Ordering 
the data in this way puts ‘vomits’ in last place, despite the 
fact that 100% of patients who vomited found the taste 
of their medicine to be unacceptable. Since so few chil-
dren vomited (n=7), the proportion of the total number 
of children who identified the taste as unacceptable and 
also displayed this behaviour (ie, the sensitivity) was low, 
at 3%. Hence, although a vomiting child is almost certain 
to find the taste unacceptable, using this behaviour in 
isolation as a predictor of negative taste would miss the 
vast majority of patients who reported taste to be negative.
Inter-rater agreement assessed via the use of short 
films and images were mixed; prevalent expressions were 
detected in >95% of cases, whereas some mild expres-
sions were only detected in 40%–50% of those viewing 
the images.
Analysis of medicine-specific taste assessment
Fifty-seven different drugs were observed in this study and 
the six most commonly administered were paracetamol, 
ibuprofen, prednisolone, co-amoxiclav, amoxicillin and 
clarithromycin, which made up 76% (n=477) of the total 
data set.
Comparisons were made across the six most commonly 
prescribed drugs. Table 3 ranks these drugs in order of 
taste, and reports the means scores on the hedonic scale 
Table 2 Relationship between facial expression or a behaviour and a patient report of an unacceptable tasting medicine
Behaviour
Cases where taste was reported as 
unacceptable (n=255)
Tau Sens.  (%) Spec. (%)Not displayed (%) Displayed (%)
Voices disgust 160/515 (31) 95/105 (90) 0.45 37 97
Eyes squeezed 131/460 (28) 124/160 (78) 0.44 49 90
Nose wrinkle 125/433 (29) 130/187 (70) 0.38 51 84
Voices resistance 184/539 (34) 71/81 (88) 0.37 28 97
Refusal 192/551 (35) 63/69 (91) 0.36 25 98
Pursed lips 168/505 (33) 87/115 (76) 0.33 34 92
Cries/screams 201/559 (36) 54/61 (89) 0.32 21 98
Brow bulge 149/463 (32) 106/157 (68) 0.31 42 86
Physical restraint 219/579 (38) 36/41 (88) 0.25 14 99
Cries 216/573 (38) 39/47 (83) 0.24 15 98
Spits out 229/590 (39) 26/30 (87) 0.21 10 99
Vomits 248/613 (40) 7/7 (100) 0.13 3 100
Table 3 Patient-reported taste scores by medicine
Drug
Hedonic score VAS score
Tastes OK?
(% ‘No’)
Composite 
outcome
% unacceptableMean
% 
unacceptable Mean (mm)
% 
unacceptable
Clarithromycin (n=26) 3.5 62 70 58 65 77
Prednisolone (n=86) 3.6 58 68 54 61 70
Amoxicillin (n=30) 2.7 37 37 23 33 43
Co-amoxiclav (n=50) 2.5 30 39 24 29 33
Paracetamol (n=193) 2.4 22 37 21 21 29
Ibuprofen (n=92) 2.1 14 27 12 12 20
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and VAS, as well as the proportion of patients answering 
‘no’ to the, ‘Did you think the medicine tasted OK?’ 
question.
The drugs can be divided into three groups based on 
these data: clarithromycin and prednisolone were found 
to be the worst tasting; amoxicillin and co-amoxiclav were 
mid-range, and ibuprofen and paracetamol were the best 
tasting medicines. The effect of brand was also investi-
gated and the data are presented in online supplemen-
tary material 3.
In addition to reports of taste, the proportion of chil-
dren who refused, vomited or spat out the medicines, was 
calculated and classified as unable to ‘use a medicinal 
product as intended’. In total, this occurred in 33/620 
(5%) administrations, which are reported for the six most 
commonly used drugs in table 4.
Clarithromycin was the most commonly not taken as 
intended and was also the drug most frequently iden-
tified as having unacceptable taste, based on the previ-
ously defined composite outcome. However, there was 
insufficient data to suggest that the taste of the medicine 
was directly related to the ability to take the medicine as 
intended. Children may vomit due to their underlying 
illness rather than as a direct result of the taste of their 
medicine.
DIsCussIOn
Few studies have categorised acceptability of the taste 
of medicines. The results within this study agree with 
previous reports, where a neutral to positive hedonic 
response indicates acceptable taste14–17; Sjövall et al18 
compared two brands of penicillin and reported that 
the acceptable taste mean hedonic score was within the 
neutral to positive range and an unacceptable taste was 
in the negative range.18 Children were free to ask for 
support in completing the PRO measured and we did not 
collect data on how many received help in this aspect; it 
would be of value to consider how many, particularly in 
the youngest age group received support. Many of the 
children aged 2–5 years were able to provide reliable data 
on the taste of medicines demonstrating that the scales 
and questions used within this study are suitable for very 
young participants.
Interpretation of facial expressions and behaviours
Voicing disgust was the behaviour most strongly associated 
with unacceptable taste while, perhaps counterintuitively, 
vomiting was the behaviour least strongly correlated with 
unacceptable taste. Despite the fact that 100% of patients 
who vomited found the taste of their medicine to be unac-
ceptable, only a small number of patients vomited (n=7). 
As a result, while vomiting was a highly specific predictor 
of unacceptable taste, it had very low sensitivity. A similar 
pattern was also observed for the other facial expressions 
and behaviours, with sensitivity ranging from 10% to 51%, 
and specificity from 84% to 99%. This can be interpreted 
as indicating that, while it was uncommon to observe 
these facial expressions and behaviours in patients who 
found the taste of the medicine acceptable, displaying 
facial expressions and behaviours was not a strong indi-
cator of unacceptability.
The behaviours used to inform the researcher obser-
vations were not always clearly defined; for example, 
the use of physical restraint was not explicitly stated and 
further work is required to better understand what phys-
ical restraint may be considered acceptable.
The explicit definition of an acceptable medicine being 
‘an overall ability of the patient and caregiver (defined 
as ‘user’) to use a medicinal product as intended (or 
authorised)’,19 includes the patient/caregiver’s ability to 
access the medicine and comply with packaging require-
ments and for this study to demonstrate that the medi-
cine was swallowed without incident. In total, 33/620 
(5%) of medicines were spat out or vomited, and there-
fore unacceptable within this in patient population. This 
demonstrates that, although some of the behaviour and 
expressions observed may link more strongly to a negative 
taste, they do not automatically mean that the medicine 
was unacceptable.
In future studies, observations should ensure that 
the medicine was taken as intended; this may require a 
simple tool to ensure that the dose was completely swal-
lowed without spitting out or vomiting. There is no need 
to include additional observations, as these were not 
strongly correlated to PROs on the taste of medicines.
Medicine-specific taste assessment
Our results correlate well with other reports in the liter-
ature on the taste of medicines. Both paracetamol and 
ibuprofen have previously been reported to demonstrate 
acceptable taste (mid-range in a five-point hedonic scale) 
in paediatric populations.20 21 Co-amoxiclav and amoxi-
cillin were reported to have acceptable taste to 57%–67% 
of children within this study, which is consistent with 
previous literature, which has reported co-amoxiclav to be 
preferred to other antibiotics in terms of taste, including 
amoxicillin.22–28 Previous work suggested that 60% of 
children accepted amoxicillin without problems and 63% 
of children liked the taste of co-amoxiclav.28 Predniso-
lone and clarithromycin were the least liked medicines, 
again consistent with published data, with results showing 
predominantly negative scores in hedonic scales or the 
Table 4 Percentage unable to take medicine as intended
Medicine
% spat out/
vomited the 
medicine
Composite 
outcome
% unacceptable
Clarithromycin (n=26) 23 77
Amoxicillin (n=30) 13 43
Prednisolone (n=86) 9 70
Co-amoxiclav (n=50) 6 33
Ibuprofen (n=92) 2 20
Paracetamol (n=193) 1 29
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equivalent of >70 mm in a VAS.3 24 29–33 This study identi-
fied differences in acceptance of certain brands of medi-
cines; however, there was insufficient sample numbers 
to undertake a detailed analysis of the impact of brand 
on taste and acceptance. A future study that explored 
brand preference would be of value to patients and those 
purchasing commonly used medicines.
Using our criteria, the proportion of patients classifying 
taste as acceptable for the most liked of the frequently 
prescribed medicines (ibuprofen and paracetamol) was 
over 70%; the proportion classifying taste as acceptable 
for the least liked medicines (prednisolone and clari-
thromycin) was less than 30%. This study provides some 
standardised values for medicines used within a UK popu-
lation, the thresholds reported here provide guidance for 
future medicines development where in addition to taste 
scores the overall risk–benefit of the medicine will need 
to be considered.
recommended tools to assess acceptability
This study has correlated three simple patient-reported 
measures of medicines taste acceptability. It has also 
provided comparative data from existing medicines. 
Regulations mandate that all new medicines need to be 
demonstrated to be acceptable to children.1 This study 
provides pragmatic and reliable tools to conduct this 
assessment. Furthermore, comparison of the results 
from a new medicine using these tools can be directly 
compared with existing medicines to support evidence of 
acceptance.
COnClusIOns
This study has generated data on the taste of medicines 
commonly used in paediatric populations aged 2–16 
years. The results of this study suggest that PRO measures 
are a reliable and valid assessment of the taste of chil-
dren’s medicines, for children aged from 2 to 16 years. 
These assessment tools offer a mechanism to evaluate 
the taste of other medicines (either novel products and 
formulations or medicines used orally in an off-label or 
unlicensed manner) to generate comparative data on the 
taste of medicines.
The data from this study coupled with previous liter-
ature on the taste of medicines provides evidence to 
suggest criteria to demonstrate acceptability of taste of 
medicines.
Our results suggest that criteria to demonstrate accept-
ability of taste are: a mean VAS score of <70 mm; a mean 
hedonic score of ≤3 (neutral or positive face) and a 
non-negative response to the ‘Tastes OK?’ question. Prag-
matically, there is no need to use all methods. As the 
hedonic scale was understood across the widest age range, 
this should be the first choice method going forwards.
It would be prudent to ensure that any new product 
exceeds these scores to demonstrate that it is likely to 
have acceptable taste in practice.
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